While the Senate bill leaves many of the ACA's provisions in place, it does so with less generous funding. » Read More
By: Elizabeth Gurdus
Jim Cramer revealed which company could have Wall Street talking next week. » Read More
Sen. Dean Heller, R-Nev., said Friday he will not support the Senate's Obamacare replacement bill in its current form. » Read More
By: John Harwood
Core Trump voters' loyalty to the president is more connected to racial solidarity, experts say. » Read More
Former Wells Fargo CEO Dick Kovacevich says Theranos is experiencing "normal things" common to start-ups.
Johnson & Johnson said it would acquire Vogue International for $3.3 billion, adding brands such as OGX shampoos and FX hair styling products.
Nearly half of all poor Texans still lack health insurance despite coverage gains in other segments of the population since the fall of 2013.
A group of scientists found that suppressing activity in key places appeared to lessen addictive and reward-seeking behavior.
The injection of stem cells into the brains of chronic stroke patients has led to promising results, Stanford University says.
From how to enroll to which options to choose, what you don’t know about Medicare could cost you.
Biotech startup NantHealth launched into the market Thursday after its initial public offering, with the stock surging nearly 33 percent.
The Gates Foundation is trying to stop Zika by giving mosquitos a sexually transmitted disease
The team tests germs for antibiotic resistance, which has become the scourge of hospitals all over the world. NBC News reports.
Rep. Gibbs says he seriously hopes President Obama reconsiders the legislation he proposed to keep the Zika virus out of the US.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
People returning from areas exposed to Zika virus should follow safer sex practices or abstain from sex for at least eight weeks, the organization said.
Jazz Pharma will buy Celator Pharma, to gain access to an investigational product in development for treating acute myeloid leukemia.
Ecstasy is becoming popular again in the European Union, with online sales and targeted marketing helping to drive the revival.
Martin Shkreli's tweet endorsement of the Republican nominee comes as he fights criminal fraud charges.
Shares of Valeant Pharmaceuticals rose more than 9 percent Friday on reports that the company rejected a joint takeover bid earlier this year.
Thermo Fisher Scientific said it would buy FEI for about $4.2 billion to gain access to its signature electron microscopy technology.
Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful.
New medicines are increasingly targeting the genetic drivers of disease. But what if medicine could go further and correct the genetic defect itself?
Scientists are working on a new treatment for depression and PTSD: deep-brain stimulation.
Get the best of CNBC in your inbox